HLN.L

Haleon plc
Haleon PLC - Transaction in Own Shares
5th June 2025, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 5049L
Haleon PLC
05 June 2025
 

 

 

Haleon plc: Transaction in own shares

 

05 June 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of the following number of ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under its share buyback programme announced on 28 March 2025 (the "Buyback Programme").

 

Date of purchase:

04 June 2025

Number of Shares purchased:

815,673

Highest price paid per share (p):

405.80

Lowest price paid per share (p):

397.10

Volume weighted average price paid per share (p):

399.61

 

Following the settlement of the above, the Company's registered share capital is 9,002,924,933 ordinary shares of £0.01 each, of which 4,080,205 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,998,844,728 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK

(the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:

 

http://www.rns-pdf.londonstockexchange.com/rns/5049L_1-2025-6-4.pdf

 

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

 

This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.

 

Enquiries


Investors

 

Media

 

Jo Russell

+44 7787 392441

Zoë Bird

+44 7736 746167

Rakesh Patel

+44 7552 484646

Victoria Durman

+44 7894 505730

Emma White

+44 7823 523562

 

 

Email: investor-relations@haleon.com


Email: corporate.media@haleon.com


 

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

 

For more information, please visit www.haleon.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSVZLFBEQLBBBZ]]>
TwitterFacebookLinkedIn